📊 PPCB Key Takeaways
Is Propanc Biopharma, Inc. (PPCB) a Good Investment?
Propanc Biopharma is a pre-revenue clinical-stage biotech facing severe financial distress with only $443.7K in cash against a $4.1M annual burn rate, providing approximately 1-2 months of runway. The company exhibits classic pre-commercial biotech economics with no revenue generation and mounting operating losses of $14.7M, with no near-term path to profitability without substantial capital infusion or strategic partnership.
Propanc Biopharma, Inc. Key Strengths (PPCB)
- Minimal debt burden (0.01x debt-to-equity) reduces financial leverage risk
- Low long-term debt of only $55.0K provides flexibility for restructuring or financing
- Current ratio of 2.37x indicates assets are liquid, though absolute amounts are concerning
PPCB Stock Risks: Propanc Biopharma, Inc. Investment Risks
- Critical liquidity crisis: $443.7K cash against $4.1M annual operating burn creates imminent solvency risk with <2 months runway
- No revenue generation and no disclosed path to commercialization; company entirely dependent on R&D success and external funding
- Severe negative returns (ROE -145.4%, ROA -99.7%) and persistent operating losses of $14.7M indicate fundamental business model challenges
- Zero insider buying in last 90 days suggests lack of confidence from management in near-term prospects
Key Metrics to Watch
- Cash balance and monthly cash burn rate (critical for survival assessment)
- Success of clinical trials and regulatory milestones (required for de-risking valuation)
- Financing activities and capital raises (essential for extending runway)
Propanc Biopharma, Inc. (PPCB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.37x current ratio provides a solid financial cushion.
PPCB Profit Margin, ROE & Profitability Analysis
PPCB vs Healthcare Sector: How Propanc Biopharma, Inc. Compares
How Propanc Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Propanc Biopharma, Inc. Stock Overvalued? PPCB Valuation Analysis 2026
Based on fundamental analysis, Propanc Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Propanc Biopharma, Inc. Balance Sheet: PPCB Debt, Cash & Liquidity
PPCB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Propanc Biopharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1,420.53 indicates the company is currently unprofitable.
PPCB Revenue Growth, EPS Growth & YoY Performance
Propanc Biopharma, Inc. Dividends, Buybacks & Capital Allocation
PPCB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Propanc Biopharma, Inc. (CIK: 0001517681)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PPCB
What is the AI rating for PPCB?
Propanc Biopharma, Inc. (PPCB) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PPCB's key strengths?
Claude: Minimal debt burden (0.01x debt-to-equity) reduces financial leverage risk. Low long-term debt of only $55.0K provides flexibility for restructuring or financing.
What are the risks of investing in PPCB?
Claude: Critical liquidity crisis: $443.7K cash against $4.1M annual operating burn creates imminent solvency risk with <2 months runway. No revenue generation and no disclosed path to commercialization; company entirely dependent on R&D success and external funding.
What is PPCB's revenue and growth?
Propanc Biopharma, Inc. reported revenue of N/A.
Does PPCB pay dividends?
Propanc Biopharma, Inc. does not currently pay dividends.
Where can I find PPCB SEC filings?
Official SEC filings for Propanc Biopharma, Inc. (CIK: 0001517681) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PPCB's EPS?
Propanc Biopharma, Inc. has a diluted EPS of $-0.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PPCB's fundamental grade?
Based on our AI fundamental analysis in May 2026, Propanc Biopharma, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PPCB stock overvalued or undervalued?
Valuation metrics for PPCB: ROE of -145.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PPCB's AI grade for 2026?
Our dual AI analysis gives Propanc Biopharma, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PPCB's free cash flow?
Propanc Biopharma, Inc.'s operating cash flow is $-4.1M, with capital expenditures of $4.9K.
How does PPCB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -145.4% (avg: 15%), current ratio 2.37 (avg: 2).